Oct.—After deciding that the treatment of substance abuse was not a major part of its business strategy, Acadia (drug discovery in neurological diseases) said it will provide seed funding to form Abbey Pharmaceuticals to focus on this therapeutic area.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?